Business Wire

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation

Share

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA® (edoxaban) in protecting against the risk of stroke in people with atrial fibrillation (AF). Over 13,000 patients were followed for two years in the ETNA-AF-Europe study, showing stroke and bleeding rates in line with rates seen after one year of follow-up. The data were presented at the annual scientific meeting of the European Heart Rhythm Association (EHRA 2021).1

“AF is a long-term condition which puts people at an increased risk of stroke, so it is very important that we have treatments that can provide benefits over the long term,” said Joris R. de Groot, MD, PhD, FESC, Professor of Cardiac Electrophysiology and Atrial Fibrillation at University of Amsterdam; Cardiologist at the Amsterdam University Medical Centers, Amsterdam the Netherlands. “We are seeing that more frail patients receiving the lower dose of edoxaban are not at increased risk of intracranial haemorrhage and are benefitting from treatment. This underlines the importance of prescribing anticoagulant therapy even for ageing AF patients.”

Event rates for stroke and death were 0.69% and 3.80% per year respectively. Some patients were prescribed the lower dose of edoxaban (30mg) for reasons including renal impairment. Annual event rates of intracranial haemorrhage were similar for both 60mg (0.2%) and 30mg (0.22%) doses. As a study investigating treatment in routine clinical practice, the data show that the majority of patients were using the recommended dose (83%).

The two-year outcome data in 13,417 patients across 10 European countries were from the European ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) programme, a non-interventional safety study evaluating edoxaban treatment in routine clinical practice for AF. ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study programme investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date.

Additional data in 27,617 people with AF from the global ETNA-AF programme were also presented at EHRA 2021, confirming that the stroke and bleeding rates under use of edoxaban at two years were also considered low and in line with randomised clinical trials in this larger, global data set. Patients with AF benefitted from edoxaban treatment across age groups, including the very elderly (≥85 years), in routine clinical care.2,3

“These data underline the importance of providing effective treatment for elderly and frail AF patients, who are already at higher risk of strokes and, as confirmed by these real-world data, benefit from edoxaban treatment,” said Dr. Garth Virgin, Executive Director Medical Affairs Specialty Medicines at Daiichi Sankyo Europe. “The ETNA-AF programme is a huge undertaking that is providing critical insights into patient outcomes in routine clinical practice, and we are truly grateful for all the healthcare professionals and patients who are helping to make it possible.”

-ENDS-

About ETNA-AF: https://www.daiichi-sankyo.eu/media/about-etna-af

About AF: https://www.daiichi-sankyo.eu/media/about-etna-af

About Edoxaban: https://www.daiichi-sankyo.eu/media/about-etna-af

About the Edoxaban Clinical Research Programme, EDOSURE: https://www.daiichi-sankyo.eu/media/about-etna-af

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

Forward-looking statements: https://www.daiichi-sankyo.eu/media/about-etna-af

References


1 De Caterina R, et al. Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study. Presentation at EHRA Congress 2021.

2 Dinshaw L, et al. Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: Results from the global noninterventional ETNA-AF program. Presentation at EHRA Congress 2021.

3 Morrone D, et al. Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across all age groups: Two-year results from ETNA-AF. Presentation at EHRA Congress 2021.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Cardiovascular Europe
+49 151 1714 7317

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EAG Expands Medical Device Testing Services with New Laboratory7.5.2021 18:22:00 EEST | Press release

EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo. The new laboratory is a bespoke design to support the requirements of the medical device industry. It increases EAG’s analytical capabilities, allows for improved turnaround times and helps meet evolving requirements from the FDA as well as the European Union Medical Device Regulations (MDR). Specialty features of the laboratory include: A cleanroom designed for particle isolation and identification A dedicated medical device polymer analysis laboratory State-of the-art instrumentation to support biocompatitility testing of ISO 10993-18 programs for medical devices and combination products EAG scientists have been investigating and resolving product failures for more than half a century and have a deep understanding of materials and testing procedures. The medical device laboratory expansion allows EAG to leverage that knowledge and apply it toward su

SoftServe Wins Learning and Development Honor at 2021 ATD Excellence in Practice Awards7.5.2021 14:00:00 EEST | Press release

SoftServe, a leading digital authority and consulting company, won the Excellence in Practice Award in the ‘Learning and Development’ category in the 2021 Association for Talent Development (ATD) Excellence in Practice Awards. SoftServe was recognized for its corporate learning hub, SoftServe University, which focuses on learning and development opportunities for associates, including the design and delivery of training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005003/en/ Association for Talent Development logo. (Photo: Business Wire) “SoftServe is dedicated to creating a people-centric organization that allows associates to grow and develop professionally,” said Galyna Datsiv, AVP of Learning and Development at SoftServe. “Our corporate learning ecosystem within the integrated talent management framework enables us to reach SoftServe’s strategic business goals by ensuring associates are qualified and have the ex

 Monument Assurance Belgium and Intégrale Reach Agreement for the Transfer of Intégrale's Entire Portfolio and Staff to MAB7.5.2021 13:26:00 EEST | Press release

Monument Assurance Belgium (“MAB”) and Intégrale have reached an agreement under which MAB will acquire the entire portfolio and all the staff of the insurance company Intégrale. This agreement follows a firm offer from MAB, which was considered by the provisional administrators appointed by the National Bank of Belgium (“NBB”) to be that which best meets the interests of Intégrale policyholders and staff. The transaction remains subject to the final approval of the NBB. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210507005270/en/ During the transition period, MAB and Intégrale will take all steps necessary to prepare for a seamless transfer for policyholders, brokers and staff. In the meantime, Intégrale's staff will continue to service policyholders and brokers as usual. In addition to the transfer of assets at the time of closing, MAB will offer an 18-month employment guarantee to all employees and, in addition, a 3-mo

The Metals Company Joins European Industry Alliances to Bolster Battery Supply Chain for the Clean Energy Transition7.5.2021 11:00:00 EEST | Press release

Today, The Metals Company (formerly DeepGreen), a developer of the world’s largest and highest-grade estimated source of battery metals, announced it has joined two of the European Union’s foremost industrial alliances—the European Raw Materials Alliance (ERMA) and the European Battery Alliance (EBA)—as the bloc advances its plans to become a global leader in the sustainable production of the batteries necessary to store clean energy and power electric vehicles (EVs). As a member of these industrial alliances, The Metals Company—which announced in March its plans to go public via a merger with the Sustainable Opportunities Acquisition Corporation (NYSE: SOAC)—brings a new, scalable source of battery metals to the table in the form of polymetallic nodules found unattached on the deep seafloor in the Pacific Ocean, which can help deliver upon their mandate for a diverse, reliable and responsible supply of critical minerals needed for low-carbon technologies. Under its Green Deal, the Eur

Morocco and UN Celebrate First-Ever International Argan Tree Day7.5.2021 09:30:00 EEST | Press release

Morocco and the United Nations will be marking the first-ever International Argan Tree Day on May 10th, 2021. The Argan tree, a tree specific to the Kingdom of Morocco, will thus be celebrated every year on May 10, as an intangible cultural heritage of humanity and ancestral source of sustainable development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005652/en/ February 22, 2021: The United Nations’ General Assembly adopted by consensus a resolution proclaiming May 10 of each year as the “International Argan Tree Day” (Photo: AETOSWire) The proclamation of the International Argan Tree Day was announced on March 3, 2021, when the UN General Assembly adopted by consensus a draft resolution initiated by Morocco and hailed by all United Nations’ member states. This milestone is a culmination of Morocco’s quest to mobilize the international community to protect and further develop the country’s Argan industry. It is al

Tigo Energy Demonstrates Optimization to Installers in Brazil with Stark Renováveis Installation7.5.2021 03:14:00 EEST | Press release

Tigo Energy, Inc., the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, announced today that Stark Renováveis has used the Tigo TS4-A-O to mitigate energy lost due to shade on their corporate headquarters in São José do Rio Preto, Brazil. Their confidence in Tigo’s solution drove the selection of the products for their own use. The Tigo solution gives installers and commercial system owners the freedom to choose their preferred inverters and panels along with the right features for optimized, monitored and PV safe systems. The Stark Renováveis team chose a rooftop PV system with 405 Wp modules organized in multiple strings and using GoodWeTM grid-tied inverters. The optimum placement of the modules was on a roof bordering a large construction wall which would ordinarily lead to shade and a degradation of the output. To mitigate the problem of energy lost due to shade, Tigo TS4-A-O optimizers were deployed to ensure the best possible system performance. "As

93rd Vifor Pharma Group Annual General Meeting6.5.2021 19:00:00 EEST | Press release

Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented. Shareholder approvals Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom